143 related articles for article (PubMed ID: 24732870)
1. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.
Ouattara EN; Ross EL; Yazdanpanah Y; Wong AY; Robine M; Losina E; Moh R; Walensky RP; Danel C; Paltiel AD; Eholié SP; Freedberg KA; Anglaret X
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):294-302. PubMed ID: 24732870
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
[TBL] [Abstract][Full Text] [Related]
3. Optimizing infant HIV diagnosis with additional screening at immunization clinics in three sub-Saharan African settings: a cost-effectiveness analysis.
Dunning L; Gandhi AR; Penazzato M; Soeteman DI; Revill P; Frank S; Phillips A; Dugdale C; Abrams E; Weinstein MC; Newell ML; Collins IJ; Doherty M; Vojnov L; Fassinou Ekouévi P; Myer L; Mushavi A; Freedberg KA; Ciaranello AL
J Int AIDS Soc; 2021 Jan; 24(1):e25651. PubMed ID: 33474817
[TBL] [Abstract][Full Text] [Related]
4. The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.
Schneider K; Nwizu C; Kaplan R; Anderson J; Wilson DP; Emery S; Cooper DA; Boyd MA
PLoS One; 2013; 8(2):e54435. PubMed ID: 23457450
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
[TBL] [Abstract][Full Text] [Related]
6. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
[TBL] [Abstract][Full Text] [Related]
7. Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.
Eholie SP; Moh R; Benalycherif A; Gabillard D; Ello F; Messou E; Zoungrana J; Diallo I; Diallo M; Bado G; Cisse M; Maiga AI; Anzian A; Toni TD; Congo-Ouedraogo M; Toure-Kane C; Seydi M; Minta DK; Sawadogo A; Sangaré L; Drabo J; Karcher S; Le Carrou J; de Monteynard LA; Peytavin G; Gabassi A; Girard PM; Chaix ML; Anglaret X; Landman R;
Lancet HIV; 2019 Nov; 6(11):e750-e759. PubMed ID: 31601544
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings.
Dugdale CM; Ufio O; Alba C; Permar SR; Stranix-Chibanda L; Cunningham CK; Fouda GG; Myer L; Weinstein MC; Leroy V; McFarland EJ; Freedberg KA; Ciaranello AL
J Int AIDS Soc; 2023 Jan; 26(1):e26052. PubMed ID: 36604316
[TBL] [Abstract][Full Text] [Related]
9. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
[TBL] [Abstract][Full Text] [Related]
10. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Brogan A; Mauskopf J; Talbird SE; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
[TBL] [Abstract][Full Text] [Related]
11. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis.
Hyle EP; Jani IV; Lehe J; Su AE; Wood R; Quevedo J; Losina E; Bassett IV; Pei PP; Paltiel AD; Resch S; Freedberg KA; Peter T; Walensky RP
PLoS Med; 2014 Sep; 11(9):e1001725. PubMed ID: 25225800
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
Mauskopf J; Brogan A; Martin S; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
[TBL] [Abstract][Full Text] [Related]
15. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.
Lorenzana SB; Hughes MD; Grinsztejn B; Collier AC; Luz PM; Freedberg KA; Wood R; Levison JH; Mugyenyi PN; Salata R; Wallis CL; Weinstein MC; Schooley RT; Walensky RP
AIDS; 2012 Jun; 26(9):1083-93. PubMed ID: 22343964
[TBL] [Abstract][Full Text] [Related]
16. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?
Scott Braithwaite R; Nucifora KA; Toohey C; Kessler J; Uhler LM; Mentor SM; Keebler D; Hallett T
AIDS; 2014 Jan; 28 Suppl 1(0 1):S73-83. PubMed ID: 24468949
[TBL] [Abstract][Full Text] [Related]
17. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA;
AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091
[TBL] [Abstract][Full Text] [Related]
18. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness.
Kimmel AD; Weinstein MC; Anglaret X; Goldie SJ; Losina E; Yazdanpanah Y; Messou E; Cotich KL; Walensky RP; Freedberg KA;
J Acquir Immune Defic Syndr; 2010 Jul; 54(3):258-68. PubMed ID: 20404739
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean.
Wolf LL; Ricketts P; Freedberg KA; Williams-Roberts H; Hirschhorn LR; Allen-Ferdinand K; Rodriguez WR; Divi N; Wong MT; Losina E
J Acquir Immune Defic Syndr; 2007 Dec; 46(4):463-71. PubMed ID: 18077836
[TBL] [Abstract][Full Text] [Related]
20. Early outcomes of darunavir- and/or raltegravir-based antiretroviral therapy in children with multidrug-resistant HIV at a pediatric center in Botswana.
Kirk BL; Gomila A; Matshaba M; Marape M; Joel DR; Anabwani G; Tolle MA
J Int Assoc Provid AIDS Care; 2013; 12(2):90-4. PubMed ID: 23315674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
